For the clinical neuroscientist, the metabolic en cephalopathies are a source of both optimism and frustration. This group of disorders is caused by failure of organs other than the brain that results in one of three basic mechanisms producing brain dysfunction: the presence of a toxin or accumula tion of a metabolic waste product, as in hyperam monemia or liver failure; deficiency of a necessary metabolic substrate, as in hypoglycemia and hyp oxia; or disruption of the internal milleau of the brain, as seen during water intoxication. When con sidering the mechanisms that are likely causes of the symptoms exhibited by patients, it is easy to feel optimistic, since restoration of the normal physiological and biochemical state should lead to a resolution of symptoms. Unfortunately, despite our best theories concerning the pathophysiology of this group of disorders, the results of treatment may be discouraging. The development of new tools for clinical investigation that are specifically designed to facilitate in vivo studies of cerebral me tabolism and physiology, such as positron-emission tomography (PET), should make it possible to ac celerate progress in the study and treatment of this group of disorders.
Liver disease, according to recent morbidity and mortality data in the United States, is the sixth ranked cause of lost years of life in adults (CDC, 1984) . Hepatic encephalopathy is very common in patients with fulminant hepatic failure and chronic cirrhosis, where neurological symptoms may lead the patient to seek medical attention. A variety of mechanisms have been postulated to account for the development of cerebral symptoms. Many data strongly implicate hyperammonemia as an impor tant cause of hepatic encephalopathy (for review see Lockwood, 1987) . High specific activity am monia is easily labeled with N-13, a cyclotron-pro duced isotope that decays exclusively by positron emission, and is well suited for metabolic studies. Previous work with this isotope (Lockwood et aI., 1979) has shown that the uptake and rate of metab olism of ammonia by the brain is a linear function of its arterial concentration. When patients were segregated according to presence or absence of he patic encephalopathy, the patients with hepatic en cephalopathy had a higher rate of cerebral am monia metabolism than did nonencephalopathic pa tients with liver disease and normal controls. Subsequent studies of ammonia metabolism by normal brain led to the development of techniques to measure cerebral ammonia extraction on a re gional basis and to compute the permeability-sur face area product (PS) for the blood-brain barrier (Lockwood et aI., 1984) . Studies of diffusion of am monia across the blood-brain barrier (BBB) in pa tients with hepatic encephalopathy are in progress based both on the report of Ehrlich et al. (1980) , which demonstrates higher brain: blood ratios of ammonia in portacaval shunted animals compared with normal animals, and the observations we have made suggesting that the PS product to ammonia may increase after portacaval shunting (Lockwood et aI., 1983) . Studies of facilitated transport across the BBB using PET and fluorodeoxyglucose (FDG) have been reported by most laboratories that use FDG, and these studies represent a strategy for in vestigating another aspect of BBB function. If these studies demonstrate an abnormality of BBB function, they will broaden our concept of this unique aspect of the anatomy of the brain.
Ammonia has a variety of effects on the brain acting as both an ion and a metabolite (Lockwood, 1987) . Animals with end-to-side portacaval shunts respond to an ammonia challenge in a fashion that varies with time. Four weeks after portacaval shunt, moderate hyperammonemia has little effect on CBF or oxygen metabolism; however, 8 weeks after portacaval shunt, the same degree of hyper ammonemia leads to marked reduction in both of these variables (Gjedde et aI., 1978) . These obser vations are consistent with clinical observations (Walker and Schenker, 1970) suggesting the devel opment of "toxin hypersensitivity" in patients with liver disease. This is an extremely important con cept that has been overlooked by most investi gators. If there is truly an alteration in the dose-re sponse curve for ammonia as the duration of hyper ammonemia lengthens, this hypothesis would have important clinical implications. If, as suggested, the brain becomes increasingly sensitive to the effects of ammonia as a function of the duration of hyper ammonemia, arterial ammonia levels ordinarily as sociated with no symptoms may produce profound hepatic encephalopathy in the sensitized patient. Studies of the cerebral metabolism of ammonia and its entry into the brain, made possible by N-13 am monia and PET, may help resolve this issue. If the sensitivity hypothesis is proven, aggressive diag nostic and therapeutic measures designed to detect and treat minimal hyperammonemia could lead to improvements in the quality of life and survival for patients with liver disease.
Although the concept of selective vulnerability of various regions of the brain to specified insults has received considerable attention in studies of hyp oxia, generalizations to the investigation of other forms of encephalopathy lags. We recently pub lished data from studies of rats with portacaval shunts (Lockwood et aI., 1986a) that are supported by preliminary data from studies of humans (Lock wood et aI., 1986b) strongly suggesting that asymp tomatic post-portacaval shunt hyperammonemia activates different brain regions to different de grees. Cerebral glucose metabolism in the cortex was less susceptible to the effects of ammonia than other, phylogenetically older brain regions: Cortex increased 12-18%, thalamic nuclei increased 26-59%, substantia nigra increased 48%, and retic ular formation increased 74%. We suggested that this alteration in the "metabolic anatomy" of the brain during hyperammonemia may explain the de velopment of some of the symptoms of hepatic en cephalopathy, which include alterations in con sciousness, impaired cognition, abnormal muscle tone, the emergence of pathological reflexes, and J Cereb Blood Flow Metab, Vol. 7, No.5, 1987 occasional movement disorders. Selective intraca rotid infusions of ammonia, again without discern ible clinical effects, activated the ventromedial hy pothalamus (a brain region that, when stimulated electrically, causes interruption of feeding). We suggested that this effect of ammonia may explain the loss of appetite that is common in patients with hepatic encephalopathy and may be the physiolog ical basis for the development of cachexia, a common physical finding in patients with chronic liver disease. To gether with findings from our ear lier study identifying skeletal muscle as a major organ for ammonia metabolism (Lockwood et aI., 1979), we theorized that cachexia, induced by ap petite suppressing effects of ammonia, may in crease the probability of developing future episodes of hyperammonemia. Loss of ammonia detoxifica tion by muscle may then lead to further appetite suppression, a worsening of the cachexia, and an increase in the cerebral sensitivity to ammonia. These issues are all deserving of further investiga tion, and it is likely that PET technology will be useful.
Considerable attention concerning the potential role of neurotransmitters, most notably -y-aminobu tyric acid (GABA), in the pathogenesis of hepatic encephalopathy as presented by Schafer and Jones (1982) . Briefly stated, this theory holds that ele vated GABA blood levels, combined with abnor malities in BBB permeability, permits vascular GABA to gain entry to the nervous system where it acts as an inhibitory neurotransmitter causing im pairment of nervous system function. Data to sup port this theory include measures of GAB A blood levels and an increased permeability of the BBB to a-amino isobutyric acid (AIB) in an animal model of acute hepatic failure.
According to the theory, excess GABA enters the nervous system and causes encephalopathy by increasing neural inhibition. Direct evaluation of the GABA system in humans has not yet been ac complished. Recently, substantial progress in the application of PET to studies of neurotransmitter function has been made in a number of laboratories with the most notable successes centered on studies of dopaminergic neurotransmission. Since GAB A and benzodiazepine receptor molecules are believed to be part of the same receptor complex, radiolabeled benzodiazepines have been synthe sized, and preliminary uptake studies have been re ported for patients with hepatic encephalopathy (Samson et aI., 1987) , these compounds may pro vide an avenue for more direct investigations of the GABA hypothesis. Unfortunately, the GABA re ceptor is a very complicated macromolecular struc-ture, containing a GAB A recogmtIOn protein, a GABA modulin, a chloride ion channel, a benzodi azepine binding protein, and a protein that couples GAB A recognition proteins and ion channels (Maz zari et aI., 1981). There are also nonspecific GABA binding sites in the brain that, with GAB A autore ceptors and the system's capacity for multiple ac tions, are likely to make these studies very difficult to perform and interpret in a completely unambig uous fashion (Enna, 1981) .
Substantial advances have been made in the un derstanding of some aspects of uremic encephalop athy, especially the dementia associated with dial ysis and the dialysis disequilibrium syndrome. The former disorder is frequently due to aluminum in toxication (Arieff, 1985) , and with steps designed to minimize the aluminum content of dialysis fluids, the incidence of the syndrome is likely to decrease. In some cases, chelation of aluminum with deferox amine has been reported to reverse symptoms (Swartz, 1985) . The disequilibrium syndrome is due to rapid removal of osmotically active particles from the intravascular compartment, and the devel opment of cerebral edema as free water enters the brain (Teschan and Arieff, 1985) . Other aspects of uremic encephalopathy have proven more resistant to investigation, and the toxin(s) responsible for the production of cerebral dysfunction remain un known. Considerable evidence suggests that abnor malities of parathyroid hormone and calcium play a role (Cooper et aI., 1978; Fraser et aI., 1985) . This hypothesis has been made more attractive by data linking intracellular calcium concentration, calmod ulin function, pH, and a variety of critical cellular regulatory mechanisms (Busa and Nuccitelli, 1984) . Since suitable isotopes of calcium that decay by positron emission do not exist and serum calcium finds its way into the brain slowly (Dienel, 1984) , PET methodology is unlikely to have a major im pact on the testing of the calcium hypothesis. Other data implicate neurotransmitter abnormalities in a fashion reminiscent of hypotheses related to liver dysfunction (Biasioli et aI, 1986) . With widespread availability of renal transplantation and chronic di alysis, the clinical problem of uremia is still evolving, and new hypotheses are likely to emerge.
Although deranged metabolism is perhaps the most common cause of coma of unknown etiology (Plum and Posner, 1982) , the names of neuroscien tists are strikingly absent from computer-generated lists of references dealing with basic mechanisms and clinical research related to this fascinating group of disorders. While the reasons for this are not clear, a number of possibilities exist. The pri mary care of patients most likely to develop metabolic encephalopathies is usually provided by inter nists, gastroenterologists, and surgeons, rather than neurologists. The majority of neuroscience studies of cerebral metabolism are related to infarc tion, hypoxia, hypoglycemia, epilepsy, and inher ited metabolic diseases of the nervous system, with secondary disorders of brain metabolism receiving little attention. Opportunities for funding may seem remote since most hypotheses relating to metabolic encephalopathies are still far removed from those testable by techniques of molecular biology, and as diseases such as AIDS gain ascendancy. Finally, the training of clinically oriented neuroscientists often gives this group of disorders little emphasis. It's all too easy to diagnose hepatic or uremic en cephalopathy without a critical evaluation of dis ease mechanisms, which remain largely unknown. Yet here is a group of disorders, which when en countered in patients, always produces the feeling that a solution to the clinical problem should be possible. Perhaps one day this will be true.
